Has anyone ever disputed this? Isn’t what we should be trying to prove whether or not that increased spending is actually providing innovation in drugs and procedures and thereby enabling other countries to put varying degrees of price controls in place without severely limiting the quality of care?
Framed in the opposite direction: could the US put in any form of price control to equalize this metric without significant impact to the continued investment in the field?